ArticleBrain pathology (Zurich, Switzerland)2015
Amyloid-aβ Peptide in olfactory mucosa and mesenchymal stromal cells of mild cognitive impairment and Alzheimer's disease patients.
Article in Brain pathology (Zurich, Switzerland), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 49 citations in OpenAlex.
- Up regulated hippocampal insulin pathway and oxidative stress are related to opposite changes in olfaction and episodic memory in a compensatory metabolic syndrome model in rats.Frontiers in cellular neuroscience · 2026Article
- Nasal Aβ42 mirrors brain amyloid dynamics and cognitive decline across the Alzheimer's disease continuum.Scientific reports · 2025Article
- Olfactory Ecto-Mesenchymal Stem Cells in Modeling and Treating Alzheimer's Disease.International journal of molecular sciences · 2024Review
- Biomarkers in Alzheimer's Disease: Are Olfactory Neuronal Precursors Useful forBrain sciences · 2024Review
- Unraveling the Link between Olfactory Deficits and Neuropsychiatric Disorders.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2023Review
- Autologous olfactory mucosa mesenchymal stem cells treatment improves the neural network in chronic refractory epilepsy.Stem cell research & therapy · 2023Article
- Neurons, Nose, and Neurodegenerative Diseases: Olfactory Function and Cognitive Impairment.International journal of molecular sciences · 2023Review
- Non-Invasive Nasal Discharge Fluid and Other Body Fluid Biomarkers in Alzheimer's Disease.Pharmaceutics · 2022Review
- Single-Cell RNA-Seq Analysis of Olfactory Mucosal Cells of Alzheimer's Disease Patients.Cells · 2022Article
- Analyzing Olfactory Neuron Precursors Non-Invasively Isolated through NADH FLIM as a Potential Tool to Study Oxidative Stress in Alzheimer's Disease.International journal of molecular sciences · 2021Review
- Developmental Potential and Plasticity of Olfactory Epithelium Stem Cells Revealed by Heterotopic Grafting in the Adult Brain.Stem cell reports · 2020Article
- Human olfactory mesenchymal stromal cells co-expressing horizontal basal and ensheathing cell proteins in culture.Biomedica : revista del Instituto Nacional de Salud · 2020Article
- Development of a High-Sensitivity Method for the Measurement of Human Nasal Aβ42, Tau, and Phosphorylated Tau.Journal of Alzheimer's disease : JAD · 2018Article
- Olfactory identification in subjective cognitive decline and mild cognitive impairment: Association with tau but not amyloid positron emission tomography.Alzheimer's & dementia (Amsterdam, Netherlands) · 2017Article
- RGS2 expression predicts amyloid-β sensitivity, MCI and Alzheimer's disease: genome-wide transcriptomic profiling and bioinformatics data mining.Translational psychiatry · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with mild cognitive impairment (MCI) or Alzheimer's disease (AD) might develop olfactory dysfunction that correlates with progression of disease. Alteration of olfactory neuroepithelium associated with MCI may be useful as predictor of cognitive decline. Biomarkers with higher sensitivity and specificity would allow to understand the biological progression of the pathology in association with the clinical course of the disease. In this study, magnetic resonance images, apolipoprotein E (ApoE) load, Olfactory Connecticut test and Montreal Cognitive Assessment (MoCA) indices were obtained from noncognitive impaired (NCI), MCI and AD patients. We established a culture of patient-derived olfactory stromal cells from biopsies of olfactory mucosa (OM) to test whether biological properties of mesenchymal stromal cells (MSC) are concurrent with MCI and AD psychophysical pathology. We determined the expression of amyloid Aβ peptides in the neuroepithelium of tissue sections from MCI and AD, as well as in cultured cells of OM. Reduced migration and proliferation of stromal (CD90(+) ) cells in MCI and AD with respect to NCI patients was determined. A higher proportion of anosmic MCI and AD cases were concurrent with the ApoE ε4 allele. In summary, dysmetabolism of amyloid was concurrent with migration and proliferation impairment of patient-derived stem cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.